Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00249405 · ClinicalTrials.gov registry record · Phase 2
Predicting Alcoholics' Treatment Responses to a Selective Serotonin Re-uptake Inhibitor (SSRI)
A Phase 2 study, sponsored by University of Cincinnati.
- Completed
- Registry status
- Phase 2
- Development phase
- 200
- Enrollment target
NCT00249405 is a Phase 2 study that has completed, run by University of Cincinnati. The registered enrollment target is 200 participants.
The verdict
NCT00249405, a Phase 2 study, has completed, sponsored by University of Cincinnati.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 200 participants
- Enrollment target
Study Summary
This study is being done to determine if citalopram is safe and effective in the treatment of alcohol dependence. A second purpose is to evaluate whether alcohol dependent individuals who differ in a specific genetic marker respond differently to citalopram. Citalopram is a drug approved by the U.S. Food and Drug Administration (FDA) for the treatment of depression. It belongs to a category of medications called selective serotonin re-uptake inhibitors or SSRIs. The U.S. FDA has not approved citalopram for the treatment of alcohol dependence. Therefore, it is being used "off-label" in this study.
Interventions
- DRUG Citalopram + MI
- BEHAVIORAL Placebo + MI
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2005-02 |
| Est. Completion | 2010-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00249405
The ClinicalTrials.gov registry entry for NCT00249405 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Cincinnati, which has 245 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Citalopram + MI is the first listed.
NCT00249405 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00249405 about?
NCT00249405 is a clinical study titled "Predicting Alcoholics' Treatment Responses to a Selective Serotonin Re-uptake Inhibitor (SSRI)". This study is being done to determine if citalopram is safe and effective in the treatment of alcohol dependence. A second purpose is to evaluate whether alcohol dependent individuals who differ in a specific genetic marker respond differently to citalopram. Citalopram is a drug approved by the U.S...
What is the current status of trial NCT00249405?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 200 participants. The study started on 2005-02. Estimated completion is 2010-10.
What interventions are being tested in trial NCT00249405?
The interventions under investigation include: Citalopram + MI (DRUG), Placebo + MI (BEHAVIORAL).
Who is sponsoring clinical trial NCT00249405?
This trial is sponsored by University of Cincinnati, which has 245 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.